Compare ADUS & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | EVO |
|---|---|---|
| Founded | 1979 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 934.1M |
| IPO Year | 2009 | N/A |
| Metric | ADUS | EVO |
|---|---|---|
| Price | $93.23 | $2.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $133.78 | $7.00 |
| AVG Volume (30 Days) | ★ 252.5K | 86.6K |
| Earning Date | 05-04-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.40 | N/A |
| EPS | ★ 1.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.17 | $1.37 |
| Revenue Next Year | $4.70 | $10.05 |
| P/E Ratio | $68.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $89.76 | $2.31 |
| 52 Week High | $124.44 | $4.80 |
| Indicator | ADUS | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 51.52 |
| Support Level | $91.12 | $2.88 |
| Resistance Level | $96.07 | $3.36 |
| Average True Range (ATR) | 3.91 | 0.10 |
| MACD | -0.43 | -0.03 |
| Stochastic Oscillator | 25.22 | 49.10 |
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.